Hurtado-Coll A - Search Results

1

Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.

Tretiakova MS, Wei W, Boyer HD, Newcomb LF, Hawley S, Auman H, Vakar-Lopez F, McKenney JK, Fazli L, Simko J, Troyer DA, Hurtado-Coll A, Thompson IM Jr, Carroll PR, Ellis WJ, Gleave ME, Nelson PS, Lin DW, True LD, Feng Z, Brooks JD. Tretiakova MS, et al. Prostate Cancer Prostatic Dis. 2016 Sep;19(3):264-70. doi: 10.1038/pcan.2016.12. Epub 2016 May 3. Prostate Cancer Prostatic Dis. 2016. PMID: 27136741 Free PMC article.

2

Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience.

Hurtado-coll A, Goldenberg SL, Klotz L, Gleave ME. Hurtado-coll A, et al. Urology. 2002 Sep;60(3 Suppl 1):45-51; discussion 51. doi: 10.1016/s0090-4295(02)01570-4. Urology. 2002. PMID: 12231047 Review.

3

Intermittent androgen suppression in prostate cancer: the Canadian experience.

Hurtado-Coll A, Goldenberg SL, Gleave ME, Klotz L. Hurtado-Coll A, et al. Urology. 2002 Sep;60(3 Suppl 1):52-6; discussion 56. doi: 10.1016/s0090-4295(02)01572-8. Urology. 2002. PMID: 12231049 Review.

4

Androgens and prostate cancer.

So AI, Hurtado-Coll A, Gleave ME. So AI, et al. World J Urol. 2003 Nov;21(5):325-37. doi: 10.1007/s00345-003-0373-9. Epub 2003 Oct 29. World J Urol. 2003. PMID: 14586548 Review.

5

Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.

Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M. Rocchi P, et al. Cancer Res. 2004 Sep 15;64(18):6595-602. doi: 10.1158/0008-5472.CAN-03-3998. Cancer Res. 2004. PMID: 15374973

6

Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.

Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME, Cox ME. Krueckl SL, et al. Cancer Res. 2004 Dec 1;64(23):8620-9. doi: 10.1158/0008-5472.CAN-04-2446. Cancer Res. 2004. PMID: 15574769

7

Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.

Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, Gleave ME, Cox ME, Rennie PS. Wafa LA, et al. Hum Pathol. 2007 Jan;38(1):161-70. doi: 10.1016/j.humpath.2006.07.003. Epub 2006 Sep 25. Hum Pathol. 2007. PMID: 16997353

8

Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.

Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, Cox ME, Huntsman DG. Rajput AB, et al. J Clin Pathol. 2007 Nov;60(11):1238-43. doi: 10.1136/jcp.2006.043810. Epub 2007 Jan 26. J Clin Pathol. 2007. PMID: 17259299 Free PMC article.

9

Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.

Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, Gleave ME. Sowery RD, et al. BJU Int. 2008 Aug;102(3):389-97. doi: 10.1111/j.1464-410X.2008.07618.x. Epub 2008 Mar 11. BJU Int. 2008. PMID: 18336596 Clinical Trial.

10

Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.

FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, Fazli L, Rajput AB, Gleave ME, Cox ME, Ostrander EA, Stanford JL, Huntsman DG. FitzGerald LM, et al. BMC Cancer. 2008 Aug 11;8:230. doi: 10.1186/1471-2407-8-230. BMC Cancer. 2008. PMID: 18694509 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

53 results

Search Page